Comparing two drug combos for relapsed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial looks at two different drug combinations given before a second stem cell transplant for multiple myeloma that has come back after first treatment. It aims to see if adding two extra drugs (bortezomib and bendamustine) to the standard drug (melphalan) works better than using the standard drug alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that came back after your first stem cell transplant.
- You are scheduled to have a second stem cell transplant as part of your second line of treatment.
- You will receive either a combination of three drugs (bortezomib, bendamustine, and melphalan) or just melphalan before your second transplant.
- You did not receive two back-to-back stem cell transplants in a row (tandem transplant) for your first or second treatment.
- You did not receive a donor (allogeneic) stem cell transplant as part of your first or second treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (daratumumab, bortezomib, and dexamethasone) against the usual combination (cyclophosphamide, bortezomib, and dexamethasone) in people with newly diagnosed multiple myeloma who also have kidney failure. The goal is to see if the new combination works better and helps protect kidney function.
This trial tests a new combination of drugs (elotuzumab, isatuximab, bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with high-risk multiple myeloma. The goal is to see if this combination is safe and effective before and after a stem cell transplant.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This trial compares two different chemotherapy drug combinations used before a stem cell transplant for multiple myeloma. The aim is to see if this new combination helps control the disease better before the transplant.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
Hear when a new Myeloma Multiple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.